These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 18065800

  • 1. Increased serum advanced glycation end products are associated with impairment in HDL antioxidative capacity in diabetic nephropathy.
    Zhou H, Tan KC, Shiu SW, Wong Y.
    Nephrol Dial Transplant; 2008 Mar; 23(3):927-33. PubMed ID: 18065800
    [Abstract] [Full Text] [Related]

  • 2. Protective effect of paraoxonase 1 of high-density lipoprotein in type 2 diabetic patients with nephropathy.
    Li C, Gu Q.
    Nephrology (Carlton); 2009 Aug; 14(5):514-20. PubMed ID: 19207863
    [Abstract] [Full Text] [Related]

  • 3. The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy.
    Shimoike T, Inoguchi T, Umeda F, Nawata H, Kawano K, Ochi H.
    Metabolism; 2000 Aug; 49(8):1030-5. PubMed ID: 10954022
    [Abstract] [Full Text] [Related]

  • 4. Apolipoprotein M predicts pre-beta-HDL formation: studies in type 2 diabetic and nondiabetic subjects.
    Plomgaard P, Dullaart RP, de Vries R, Groen AK, Dahlbäck B, Nielsen LB.
    J Intern Med; 2009 Sep; 266(3):258-67. PubMed ID: 19457058
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A study on serum advanced glycation end products and its association with oxidative stress and paraoxonase activity in type 2 diabetic patients with vascular complications.
    Bansal S, Chawla D, Siddarth M, Banerjee BD, Madhu SV, Tripathi AK.
    Clin Biochem; 2013 Jan; 46(1-2):109-14. PubMed ID: 23103709
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. HDL oxidability and its protective effect against LDL oxidation in Type 2 diabetic patients.
    Sanguinetti SM, Brites FD, Fasulo V, Verona J, Elbert A, Wikinski RL, Schreier LE.
    Diabetes Nutr Metab; 2001 Feb; 14(1):27-36. PubMed ID: 11345163
    [Abstract] [Full Text] [Related]

  • 10. Myeloperoxidase and paraoxonase-1 in type 2 diabetic patients.
    Jornayvaz FR, Brulhart-Meynet MC, James RW.
    Nutr Metab Cardiovasc Dis; 2009 Nov; 19(9):613-9. PubMed ID: 19201174
    [Abstract] [Full Text] [Related]

  • 11. Cellular cholesterol efflux to serum is impaired in diabetic nephropathy.
    Zhou H, Tan KC, Shiu SW, Wong Y.
    Diabetes Metab Res Rev; 2008 Nov; 24(8):617-23. PubMed ID: 18802933
    [Abstract] [Full Text] [Related]

  • 12. Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: relevance to diabetes.
    Rosenblat M, Karry R, Aviram M.
    Atherosclerosis; 2006 Jul; 187(1):74-81. PubMed ID: 16229851
    [Abstract] [Full Text] [Related]

  • 13. Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients.
    Popa C, van Tits LJ, Barrera P, Lemmers HL, van den Hoogen FH, van Riel PL, Radstake TR, Netea MG, Roest M, Stalenhoef AF.
    Ann Rheum Dis; 2009 Jun; 68(6):868-72. PubMed ID: 18635596
    [Abstract] [Full Text] [Related]

  • 14. Serum paraoxonase-I activity is unaffected by short-term administration of simvastatin, bezafibrate, and their combination in type 2 diabetes mellitus.
    Dullaart RP, de Vries R, Voorbij HA, Sluiter WJ, van Tol A.
    Eur J Clin Invest; 2009 Mar; 39(3):200-3. PubMed ID: 19260949
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Relationship between total oxidant status and severity of diabetic nephropathy in type 2 diabetic patients.
    Aslan M, Sabuncu T, Kocyigit A, Celik H, Selek S.
    Nutr Metab Cardiovasc Dis; 2007 Dec; 17(10):734-40. PubMed ID: 17321120
    [Abstract] [Full Text] [Related]

  • 17. Advanced glycation end products assessed by skin autofluorescence in type 1 diabetics are associated with nephropathy, but not retinopathy.
    Chabroux S, Canouï-Poitrine F, Reffet S, Mills-Joncour G, Morelon E, Colin C, Thivolet C.
    Diabetes Metab; 2010 Apr; 36(2):152-7. PubMed ID: 20137994
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis: correlation with low molecular AGE adduct clearance.
    Gugliucci A, Mehlhaff K, Kinugasa E, Ogata H, Hermo R, Schulze J, Kimura S.
    Clin Chim Acta; 2007 Feb; 377(1-2):213-20. PubMed ID: 17118352
    [Abstract] [Full Text] [Related]

  • 20. Increased LCAT activity and hyperglycaemia decrease the antioxidative functionality of HDL.
    Kappelle PJ, de Boer JF, Perton FG, Annema W, de Vries R, Dullaart RP, Tietge UJ.
    Eur J Clin Invest; 2012 May; 42(5):487-95. PubMed ID: 21955281
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.